After windfall 2021, covid-19 vaccine makers eye windfall 2022

Covid-19 vaccines have turned out to be high-margin products for manufacturers. With the coronavirus continuing to be around, vaccine demand remains brisk, and their manufacturers are bracing for another record year of revenues and profits.

from mint - Science https://ift.tt/3fbp04r
https://ift.tt/eA8V8J